Controversial Ginkgo Will Team With Persephone On Bacterial Delivery Of Microbial Therapies
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
You may also be interested in...
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.